Aptorum, Diamir Publish microRNA Glioblastoma Biomarker Study
Aptorum Group and DiamiR Biosciences reported peer‑reviewed evidence that plasma microRNA signatures can detect glioblastoma, publishing feasibility findings in...
Polyrizon Launches GMP Manufacturing for U.S. Clinical Trial
Polyrizon has completed GMP manufacturing of clinical trial material for its lead intranasal hydrogel after two prior development batches...
First Volunteer Dosed in Innocare’s New VAV1 Degrader Trial
InnoCare has dosed the first healthy volunteer in China with ICP-538, an oral VAV1-directed molecular glue degrader. It is...
Greenwich LifeSciences Switched Drug Product Mid-Pivotal Trial. The FDA Has Rules About That.
Greenwich LifeSciences announced mid-trial use of commercially manufactured GP2 in its Phase III FLAMINGO-01 study. What looks like a...
First Patient Dosed in Bioversys’ Phase 2b ALPE TB Trial
In earlier clinical work, the alpibectir–ethionamide combination (AlpE) delivered a 7‑day early bactericidal activity signal comparable to isoniazid and...
BBP-418 Shows Efficacy, Safety in Phase 3 LGMD2I/R9 Study
BridgeBio’s BBP-418 delivered functional and biomarker gains in the Phase 3 FORTIFY interim analysis for LGMD2I/R9: at 12 months,...
Solid Biosciences Duchenne Trial Sees Positive Interim Update
In updated interim data from the Phase 1/2 INSPIRE DUCHENNE study, 40 participants have received SGT-003 to date. Among...
Injectable Buprenorphine Lowers OUD Healthcare Costs, Study
Patients adherent to the monthly extended-release buprenorphine injection for 12 months posted 42% lower adjusted non-MOUD medical costs compared...
Breakthrough Diabetes Study: Positive Results Past One Year
At 14 months post-transplant, a single patient in an investigator-sponsored study maintained detectable fasting and meal-stimulated C-peptide, with mixed-meal...
Vima’s Hope: First Dystonia Patient Dosed in Phase 2 Study
Phase 1 data for VIM0423 showed the oral agent was safe and well tolerated through 28 days in healthy...